Synapsim's action-potential stimulation technology delivers clinically validated chronic pain relief at home — at a fraction of the cost of hospital-based neuromodulation. A R1,500 device replaces therapies that once cost R150,000.
Synapsim's APS engine doesn't mask pain. It retrains the nervous system — creating lasting reduction rather than temporary relief.
Proprietary frequency-modulation algorithms targeting nerve action potentials directly. Where TENS masks surface pain, APS retrains neural pain pathways. Protected by 3 provisional patents filed by the CTO's team.
iOS and Android apps capture daily VAP pain scores, automatically optimise treatment protocols, and feed a clinician-facing dashboard. POPIA and HIPAA compliant data on AWS South Africa infrastructure with Vula Mobile integration.
SAHPRA Class IIb · ISO 13485 · IEC 60601-1 · IEC 60601-1-11 home-use · IEC 60601-1-2 EMC (TÜV) · IEC 62304 software. CE Mark in progress. Zero adverse events across the complete clinical cohort.
3 provisional patents covering the APS frequency engine, adaptive protocol algorithms, and electrode interface. "Synapsim" trademark registered in SA; US, EU, and UK applications filed simultaneously.
ISO 13485-certified Cape Town manufacturer. Full post-market surveillance. 70% gross margin on device hardware. Designed for scale: from 23,803 units in Year 1 to 210,000 units over a 5-year SA programme.
Available via your treating physician, Clicks and Dis-Chem pharmacies, and directly online — with clinician-guided onboarding no matter how you order. Vula Mobile integration extends access to rural and underserved communities across all nine provinces.
Pilot study · N=25 chronic pain patients · 6 weeks · 2025 · VAP scoring
18 million South Africans live with chronic pain — roughly 30% of the adult population. Most have no safe, accessible, home-based solution.
Chronic back, neck, joint pain, fibromyalgia, and degenerative disc conditions affecting mobility and daily quality of life.
Diabetic neuropathy, post-herpetic neuralgia, peripheral neuropathy, and central sensitisation syndromes.
Post-operative chronic pain following orthopaedic, abdominal, or thoracic surgery — including failed back surgery syndrome.
Injury-related chronic pain, CRPS, and phantom limb pain conditions following trauma or amputation.
Repetitive strain injuries and work-related musculoskeletal disorders affecting workforce participation and productivity.
Trigger-point related myofascial pain syndrome, tension-type pain patterns, and connective tissue conditions.
15+ years medical device commercialisation with prior successful exits. Leads SA health partnerships, regulatory strategy, and the R28M Series A raise.
Biomedical engineer with 5 granted patents. Designed the APS frequency-modulation engine, proprietary electrode interface, and embedded firmware architecture.
20 years pain medicine. Designed the VAP outcome methodology, APS treatment protocols, and leads the Wits University Pain Management Clinic partnership.
Former SAHPRA senior evaluator. Leads CE Mark submission and global regulatory strategy including US FDA 510(k) pathway planning.
Ask your GP, pain specialist, or physiotherapist about Synapsim. Accredited clinicians can prescribe and set up your device directly — with ongoing remote monitoring through the clinician dashboard.
Synapsim is available through Clicks and Dis-Chem pharmacies. Walk in, speak to the healthcare team, and leave with your device — clinician onboarding is completed through the app within 24 hours.
Order directly through this site. Your device ships within 3–5 business days anywhere in South Africa. A Synapsim-accredited clinician contacts you within 24 hours to guide your onboarding remotely.
R1,500 device · 30-day free trial · R50/month subscription · SAHPRA certified